Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

Sodium-glucose co-transporter 2 inhibitors and bladder cancer - a causal association or detection bias? An international multicenter cohort study.

Funder: Canadian Institutes of Health Research

Funding period
CAD 50 K
USD 37 K
Funding amount
Abstract
Type 2 diabetes is one of the fastest growing diseases in Canada, with approximately 60,000 new patients diagnosed each year. In recent years, there have been major advancements in the treatment of type 2 diabetes with the discovery of new drug classes, such as the sodium-glucose co-transporter 2 (SGLT2) inhibitors. SGLT2 inhibitors have become increasingly popular, as they effectively lower blood sugar levels without the side effects of other antidiabetic drugs. However, these drugs have been associated with frequent urinary tract infections, and there are signals from trials that they may be associated with an increased risk of bladder cancer. To date, however, no study has been conducted in the real-world setting to assess this association. Thus, to address this gap in knowledge, I will conduct a multicenter cohort study among patients with type 2 diabetes using data sources from Canada, Europe and the Middle East. As a possible association may be explained by increased screening of the urinary tract, this international study will be specifically designed to differentiate between a possible biological effect and detection bias. Thus, this study will provide much needed information on the safety of SGLT2 inhibitors, and will be of value to regulatory agencies, physicians, and patients.
Similar projects All >
Sorted by: Start Date
Project list item
Combatting Bladder Cancer by Inducing Epithelial Turnover

National Cancer Institute to SOMAN N ABRAHAM

USD 203,510
2019 - 2021
Project list item
The role of a new molecular driver in bladder cancer

National Cancer Institute to DALEY MORERA

USD 45,016
2018 - 2021
Project list item
Novel 3D personalized bladder cancer model on demand: A new era for personalized medicine.

Canadian Institutes of Health Research to Alan I So, Claudia Itze Chavez-munoz

USD 141,091
2018 - 2020
Project list item
Immune targeting of the V600E B-Raf neo-antigen in canine urothelial carcinoma

V Foundation for Cancer Research to Nicola J Mason

USD 91,573
2018 - 2020
Project list item
Exploiting candida and UPEC interactions with immune cells for the treatment of urinary tract infections and bladder cancer

Israel Science Foundation to Ofer Mandelboim, Gilad Bachrach, Ronen Ben-Ami, Francesca Levi-Schaffer, Nir Osherov

USD 2,028,658
2018 - 2021

System

Categories
  • FOR (ANZSRC)

    1117 Public Health and Health Services

  • RCDC

    Diabetes

  • RCDC

    Cancer

  • RCDC

    Clinical Research

  • RCDC

    Patient Safety

  • RCDC

    Prevention

  • RCDC

    Urologic Diseases

  • HRCS HC

    Metabolic and Endocrine

  • HRCS HC

    Cancer

  • HRCS RAC

    5.1 Pharmaceuticals

  • Health Research Areas

    Population & Society

  • Broad Research Areas

    Public Health